Gilead Unveils Long-Term Data on Lenacapavir and New HIV Treatment Regimens at AIDS 2026
Event summary
- Gilead will present new long-term data on lenacapavir for HIV prevention at AIDS 2026, showing high efficacy and adherence in open-label extension phases of PURPOSE 1 and PURPOSE 2 trials.
- First full results from the joint Gilead-Merck Phase 3 ISLEND trials evaluating a novel once-weekly oral HIV treatment regimen will be unveiled.
- Gilead expands access strategy for lenacapavir, increasing no-profit supply program reach to up to 3 million people through 2028 in partnership with PEPFAR and The Global Fund.
The big picture
Gilead's presentation at AIDS 2026 underscores its leadership in HIV innovation, with a focus on long-acting therapies and expanded access. The company's strategic partnerships and pipeline advancements aim to address unmet needs in prevention and treatment, particularly in high-burden regions. The shift towards twice-yearly dosing options could redefine adherence and patient outcomes in the HIV space.
What we're watching
- Regulatory Pathways
- The pace at which Gilead advances regulatory filings for lenacapavir in Latin America through PAHO collaborations.
- Market Adoption
- Whether the long-term efficacy and safety data of lenacapavir will accelerate its uptake as a preferred PrEP option.
- Pipeline Progress
- How the Phase 3 results for the islatravir/lenacapavir combination could reshape the landscape for long-acting HIV treatments.